The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease

Vaccine

Volumn 29, Issue 18, 2011, Pages 3363-3371

  Harrison, Lee H ^a   Pelton, Stephen I ^b   Wilder Smith, Annelies ^c   Holst, Johan ^d   Safadi, Marco A P ^e   Vazquez, Julio A ^f   Taha, Muhamed Kheir ^g   LaForce, F Marc ^h   von Gottberg, Anne ⁱ   Borrow, Ray ^j,k   Plotkin, Stanley A ^l  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b BOSTON UNIVERSITY   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e Santa Casa de Sao Paulo   (Brazil)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g INSTITUT PASTEUR   (France)

^h PATH   (France)

ⁱ NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^j PUBLIC HEALTH ENGLAND   (United Kingdom)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Epidemiology; Meningitis; Meningococcal disease; Vaccinology; Worldwide

Indexed keywords

BACTERIAL VACCINE; MCV4 CRM; MCV4 DT; MENAFRIVAC; MENINGOCOCCUS VACCINE; MPSV 4; UNCLASSIFIED DRUG;

AFRICA; ANTIBODY TITER; ASIA; CANADA; CONFERENCE PAPER; DRUG COST; DRUG EFFICACY; EUROPE; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; INCIDENCE; MEDICAL RESEARCH; MEDICAL SOCIETY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; TRAVEL; UNITED STATES;

HUMANS; IMMUNIZATION PROGRAMS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; POPULATION SURVEILLANCE; PUBLIC HEALTH; VACCINES, CONJUGATE;

EID: 79954802756     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.058     Document Type: Conference Paper

References (78)

1. World Health Organization. Weekly epidemiological record. October 4, 2002. Available at: [Accessed August 24, 2010]. http://www.who.int/immunization/wer7740meningococcal_Oct02_position_paper.pdf.
2. Branco R.G., Amoretti C.F., Tasker R.C. Meningococcal disease and meningitis. J Pediatr (Rio J) 2007, 83(Suppl 2):S46-53.
3. Fellick J.M., Sills J.A., Marzouk O., Hart C.A., Cooke R.W., Thomson A.P. Neurodevelopmental outcome in meningococcal disease: a case-control study. Arch Dis Child 2001, 85:6-11.
4. Erickson L.J., De Wals P., McMahon J., Heim S. Complications of meningococcal disease in college students. Clin Infect Dis 2001, 33:737-739.
5. Kaplan S.L., Schutze G.E., Leake J.A., Barson W.J., Halasa N.B., Byington C.L., et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006, 118:e979-e984.
6. World Health Organization Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol Rec 2005, 80:313-320. Available at: http://www.who.int/wer/2005/wer8037.pdf [Accessed August 24, 2010].
7. Centers for Disease Control. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Neisseria meningitidis; 2009. Available at: [Accessed August 24, 2010]. http://www.cdc.gov/abcs/reports-findings/survreports/mening09.pdf.
8. National Advisory Committee on Immunization (NACI): an advisory statement: update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. Canada Communicable Disease Report; April 2009, vol. 36, ACS-3. Available at: [Accessed August 24, 2010]. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09pdf/acs-dcc-3.pdf.
9. Invasive Neisseria meningitidis in Europe 2006 2006, European Union Invasive Bacterial Infections Surveillance Network, Available at: http://www.euibis.org/documents/2006_meningo.pdf [Accessed August 24, 2010].
10. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl 2):B51-63.
11. Whitney A.M., Coulson G.B., von Gottberg A., Block C., Keller N., Mayer L.W., et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol 2009, 47:2787-2793.
12. Agudelo C.I., Sanabria O.M., Ovalle M.V. Serogroup Y meningococcal disease, Colombia [letter]. Emerg Infect Dis 2008, Available from: http://www.cdc.gov/EID/content/14/6/990.htm [Accessed November 12, 2010].
13. Abad R., Agudelo C.I., Brandileone M.C., Chanto G., Gabastou J.M., Hormazabal J.C., et al. Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region. J Infect 2009, 59:104-114.
14. Health Protection Agency. Reported deaths due to invasive meningococcal disease by age and calendar year; 2000-2008, source ONS. Available at: [Accessed June 22, 2009]. http://www.hpa.org.uk/webw/HPAweb%26HPAwebPrinterFriendly/HPAweb_C/1234859709864%3Fp=1201094595391.
15. Czumbel I, Jansson A, Celentano LP, Gauci AA. European Center for Disease Prevention and Control. Epidemiology of invasive meningococcal disease (IMD) in Europe, 2007. Presented at: Virtual Poster Session. Stockholm, Sweden: European Center for Disease Prevention and Control. Available at: [Accessed November 4, 2010]. http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/Eurovaccine/Documents/0912-eurovaccine-ID7-Czumbel-inv-meningococcal-disease-Europe-2007.pdf.
16. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50:184-191.
17. Harrison L.H., Kreiner C.J., Shutt K.A., Messonnier N.E., O'Leary M., Stefonek K.R., et al. Risk factors for meningococcal disease in students in grades 9-12. Pediatr Infect Dis J 2008, 27:193-199.
18. MacLennan J., Kafatos G., Neal K., Andrews N., Cameron J.C., Roberts R., et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006, 12:950-957.
19. Campagne G., Schuchat A., Djibo S., Ousseini A., Cisse L., Chippaux J.P. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-1996. Bull World Health Org 1999, 77:499-508.
20. Leimkugel J., Hodgson A., Forgor A.A., Pflüger V., Dangy J.P., Smith T., et al. Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight-year longitudinal study in northern Ghana. PLoS Med 2007, 4:e101.
21. Doença Meningocócica. CASOS, COEF. De incidência (por 100.000 hab) e porcentagens de doença meningocócica Segundo faixa etária estado de São Paulo-1998 a 2010. Available at: [Accessed August 24, 2010]. http://www.cve.saude.sp.gov.br/htm/resp/dm_cfeta.htm.
22. Sáfadi M.A., Cintra O.A. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010, 32:263-271.
23. Harrison L.H., Jolley K.A., Shutt K.A., et al. Maryland Emerging Infections Program. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006, 193:1266-1274.
24. Greenwood B. Manson lecture meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93:341-353.
25. Weidlich L., Baethgen L.F., Mayer L.W., Moraes C., Klein C.C., Nunes L.S., et al. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W-135:P1.5,2:ST-11 clone in Southern Brazil. J Infect 2008, 57:324-331.
26. Xiao FL. Personal communication. GMI Summit Meeting, Barcelona, Spain. June 18-19, 2010.
27. Nair D., Dawar R., Deb M., Capoor M.R., Singal S., Upadhayay D.J., et al. Outbreak of meningococcal disease in and around New Delhi, India, 2005-2006: a report from a tertiary care hospital. Epidemiol Infect 2009, 137:570-576.
28. Hossain M.A., Ahmed D., Ahmed T., Islam N., Breiman R.F. Increasing isolations of Neisseria meningitidis serogroup A from blood and cerebrospinal fluid in Dhaka, Bangladesh, 1999-2006. Am J Trop Med Hyg 2009, 80:615-618.
29. Gupta S and Saha S. Personal communication. GMI Summit Meeting, Barcelona, Spain. June 18-19, 2010; GMI Steering Committee Meeting, Short Hills Hilton, NJ, United States, November 5-6, 2009.
30. Stephens D.S. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 2009, 27(Suppl 2):B71-B77. Epub 2009 May 23.
31. Moore P.S., Harrison L.H., Telzak E.E., Ajello G.W., Broome C.V. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 1988, 260:2686-2689.
32. Wilder-Smith A., Barkham T.M., Earnest A., Paton N.I. Acquisition of W-135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. BMJ 2002, 325:365-366.
33. Wilder-Smith A., Goh K.T., Barkham T., Paton N.I. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W-135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003, 36:679-683.
34. Moore P.S., Reeves M.W., Schwartz B., Gellin B.G., Broome C.V. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989, 2:260-263.
35. Wilder-Smith A., Chow A., Goh K.T. Emergence and disappearance of W-135 meningococcal disease. Epidemiol Infect 2010, 138:976-978.
36. Cochi S.L., Markowitz L.E., Joshi D.D., Owens R.C., Stenhouse D.H., Regmi D.N., et al. Control of epidemic group A meningococcal meningitis in Nepal. Int J Epidemiol 1987, 16:91-97.
37. Pollard A.J., Shlim D.R. Epidemic meningococcal disease and travel. J Travel Med 2002, 9:29-33.
38. Corless C.E., Guiver M., Borrow R., Edwards-Jones V., Fox A.J., Kaczmarski E.B. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J Clin Microbiol 2001, 39:1553-1558.
39. Gurley E.S., Hossain M.J., Montgomery S.P., Petersen L.R., Sejvar J.J., Mayer L.W., et al. Etiologies of bacterial meningitis in Bangladesh: results from a hospital-based study. Am J Trop Med Hyg 2009, 81:475-483.
40. Gray S., Campbell H., Marsh J., Carr A., Newbold L., Mallard R., et al. The epidemiology and surveillance of meningococcal disease in England and Wales. Poster P041. 17th International Pathogenic Conference (IPNC) 2010, Available at: http://neisseria.org/ipnc/2010/IPNC_2010_abstracts.pdf [Accessed November 3, 2010].
41. Sacchi C.T., Fukasawa L.O., Gonçalves M.G., Salgado M.M., Shutt K.A., Carvalhanas T.R., et al. Incorporation of RT-PCR into routine public health surveillance for meningococcal meningitis in São Paulo State, Brazil. Poster P042, 17th International Pathogenic Neisseria Conference (IPNC) 2010, Available at: http://neisseria.org/ipnc/2010/IPNC_2010_abstracts.pdf [Accessed November 3, 2010].
42. World Health Organization Control of epidemic meningococcal disease. WHO practical guidelines 1998, Available at: www.who.int/csr/resources/publications/meningitis/whoemcbac983.pdf [Accessed February 1, 2011]. 2nd ed.
43. Centers for Disease Control Pediatric bacterial meningitis surveillance-African region, 2002-2008. MMWR Morb Mortal Wkly Rep 2009, 58:493-497.
44. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998, 280:1685-1689.
45. Beernink P.T., Caugant D.A., Welsch J.A., Koeberling O., Granoff D.M. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009, 199:1360-1368.
46. Granoff D.M., Harrison L.H., Pelton S. Meningococcal vaccines. Vaccines 2011, Saunders Elsevier, Amsterdam, The Netherlands. 6th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
47. Trotter C.L., Ramsey M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007, 31:101-107. Published December 1, 2006 ahead of print.
48. National Immunisation Program Schedule, Australia. Available at: [Accessed November 4, 2010]. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips2.
49. Borrow R., Andrews N., Findlow H., Waight P., Southern J., Crowley-Luke A., et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010, 17:154-159.
50. LaForce F.M., Ravenscroft N., Djingarey M., Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27S:B13-B19.
51. World Health Organization. A new meningitis vaccine for Africa. Available at: [Accessed February 7, 2011]. http://www.who.int/features/2010/meningitis_vaccine/en/index.html.
52. Centers for Disease Control Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 2005, 54(RR-7):1-21.
53. Centers for Disease Control Updated recommendation from the advisory committee on immunization practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. Morb Mortal Wkly Rep 2009, 58:1042-1043.
54. Cohn A. Optimizing the Adolescent Meningococcal Vaccination Program. Presentation given at the Advisory Committee on Immunization Practices (ACIP) meeting; October 2010. Available at: [Accessed November 12, 2010]. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/02-5-mening-mcv4.pdf.
55. Velentgas P. Meningococcal Vaccine Study Final Study Result. Available at: [Accessed November 4, 2010]. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun10/03-2-mening.pdf.
56. Jackson L.A., Baxter R., Reisinger K., Karsten A., Shah J., Bedell L., et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009, 49:e1-10.
57. Galloway Y., Stehr-Green P., McNicholas A., O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009, 38:413-418.
58. Sotolongo Padrón F., Campa H., Casanueva Gil V., Fajardo Díaz E.M., Cuevas Valdespino I.E., González Gotera N. Cuban meningococcal BC vaccine: experiences and contributions from 20 years of application. MEDICC Rev 2007, 9:16-22.
59. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281:1520-1527. [Comment in: JAMA. 1999;281:1541-3].
60. Sacchi C.T., Whitney A.M., Popovic T., Beall D.S., Reeves M.W., Plikaytis B.D., et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000, 182:1169-1176. Epub 2000 Sep 8.
61. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
62. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29:e71-e79.
63. LaForce F.M., Konde K., Viviani S., Preziosi M.P. The meningitis vaccine project. Vaccine 2007, 25(Suppl 1):A97-A100.
64. Meningitis Vaccine Project. Epidemics in Africa. Available at [Accessed November 24, 2010]. http://www.meningvax.org/epidemics-africa.php.
65. Coulson G.B., von Gottberg A., du Plessis M., Smith A.M., de Gouveia L., Klugman K.P. Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis 2007, 13:273-281.
66. von Gottberg A., Du Plessis M., Cohen C., Prentice E., Schrag S., de Gouveia L., et al. Group for enteric, respiratory and meningeal disease surveillance in South Africa. Emergence of endemic serogroup W-135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008, 46:377-386.
67. Ramsay M, Fox A. Invasive Neisseria meningitidis In Europe 2006. London: Health Protection Agency. Available at: [Accessed November 8, 2010]. http://www.euibis.org/documents/2006_meningo.pdf.
68. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999, 179:1569-1572.
69. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006, 25:79-80.
70. Maiden M.C., Ibarz-Pavón A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
71. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365-366.
72. Deghmane A.E., Parent du Chatelet I., Szatanik M., Hong E., Ruckly C., Giorgini D., et al. Emergence of new virulent Neisseria meningitidis serogroup C sequence type 11 isolates in France. J Infect Dis 2010, 202:247-250.
73. Snape M.D., Kelly D.F., Lewis S., Clutterbuck E.A., Lewis S., Blanchard Rohner G., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008, 336:1487-1491.
74. Sexton K., Lennon D., Oster P., Crengle S., Martin D., Mulholland K., et al. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J 2004, 117:U1015.
75. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166:817-823.
76. New Zealand Ministry of Health. Immunisation: meningococcal B (MeNZB™). Available at: [Accessed August 24, 2010]. http://www.moh.govt.nz/moh.nsf/indexmh/immunisation-diseasesandvaccines-menzb.
77. Ministry of Hajj, Kingdom of Saudi Arabia. Important Notices. Visas. Available from: [Accessed September 24, 2010]. http://www.hajinformation.com/main/p10.htm.
78. Neal K.R., Nguyen-Van-Tam J., Monk P., O'Brien S.J., Stuart J., Ramsay M. Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation. Epidemiol Infect 1999, 122:351-357.